U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C76H52O46.C9H13N
Molecular Weight 1836.4047
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROAMPHETAMINE TANNATE

SMILES

C[C@H](N)CC1=CC=CC=C1.OC2=CC(=CC(O)=C2O)C(=O)OC3=CC(=CC(O)=C3O)C(=O)OC[C@H]4O[C@@H](OC(=O)C5=CC(O)=C(O)C(OC(=O)C6=CC(O)=C(O)C(O)=C6)=C5)[C@H](OC(=O)C7=CC(O)=C(O)C(OC(=O)C8=CC(O)=C(O)C(O)=C8)=C7)[C@@H](OC(=O)C9=CC(O)=C(O)C(OC(=O)C%10=CC(O)=C(O)C(O)=C%10)=C9)[C@@H]4OC(=O)C%11=CC(O)=C(O)C(OC(=O)C%12=CC(O)=C(O)C(O)=C%12)=C%11

InChI

InChIKey=LZHILFCCEFOKOG-VFRRKMCSSA-N
InChI=1S/C76H52O46.C9H13N/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;1-8(10)7-9-5-3-2-4-6-9/h1-20,52,63-65,76-101H,21H2;2-6,8H,7,10H2,1H3/t52-,63-,64+,65-,76+;8-/m10/s1

HIDE SMILES / InChI
DEXTROAMPHETAMINE TANNATE is a salt of dextroamphetamine, amphetamine enantiomer. It is used as CNS stimulant in the treatment of attention deficit hyperactivity disorder.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Synatan

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg single, intravenous
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Sources:
unhealthy, 36.0 years (range: 20-58 years)
n = 64
Health Status: unhealthy
Condition: depression
Age Group: 36.0 years (range: 20-58 years)
Sex: M+F
Population Size: 64
Sources:
20 mg 2 times / day multiple, oral (max)
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
chlorothiazide(1-2 g)
Sources:
unhealthy, 6-9 years
n = 5
Health Status: unhealthy
Condition: hyperactivity
Age Group: 6-9 years
Sex: M
Population Size: 5
Sources:
Disc. AE: Psychiatric disorders...
AEs leading to
discontinuation/dose reduction:
Psychiatric disorders (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Psychiatric disorders 2 patients
Disc. AE
20 mg 2 times / day multiple, oral (max)
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
chlorothiazide(1-2 g)
Sources:
unhealthy, 6-9 years
n = 5
Health Status: unhealthy
Condition: hyperactivity
Age Group: 6-9 years
Sex: M
Population Size: 5
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
weak (co-administration study)
Comment: Lisdexamfetamine dimesylate (LDX), a prodrug of d-amphetamine, does not affect CYP2C19 activity in vitro. In a clinical trial a small C max reduction for omeprazole and its metabolite was observed, possibly reflecting an effect either on the activity of CYP2C19 or omeprazole absorption.
no
no
no
no
no
no
Drug as victim
Name Type Language
DEXTROAMPHETAMINE TANNATE
MI  
Common Name English
TANPHETAMIN
Brand Name English
SYNATAN
Brand Name English
DEXTROAMPHETAMINE TANNATE [MI]
Common Name English
Code System Code Type Description
CAS
1407-85-8
Created by admin on Fri Dec 15 15:16:12 UTC 2023 , Edited by admin on Fri Dec 15 15:16:12 UTC 2023
PRIMARY
MERCK INDEX
m4226
Created by admin on Fri Dec 15 15:16:12 UTC 2023 , Edited by admin on Fri Dec 15 15:16:12 UTC 2023
PRIMARY Merck Index
FDA UNII
500Y9JV943
Created by admin on Fri Dec 15 15:16:12 UTC 2023 , Edited by admin on Fri Dec 15 15:16:12 UTC 2023
PRIMARY
PUBCHEM
72710632
Created by admin on Fri Dec 15 15:16:12 UTC 2023 , Edited by admin on Fri Dec 15 15:16:12 UTC 2023
PRIMARY